JP2010513539A5 - - Google Patents

Download PDF

Info

Publication number
JP2010513539A5
JP2010513539A5 JP2009542980A JP2009542980A JP2010513539A5 JP 2010513539 A5 JP2010513539 A5 JP 2010513539A5 JP 2009542980 A JP2009542980 A JP 2009542980A JP 2009542980 A JP2009542980 A JP 2009542980A JP 2010513539 A5 JP2010513539 A5 JP 2010513539A5
Authority
JP
Japan
Prior art keywords
seq
heavy chain
light chain
amino acid
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009542980A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513539A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/078568 external-priority patent/WO2008079466A1/en
Publication of JP2010513539A publication Critical patent/JP2010513539A/ja
Publication of JP2010513539A5 publication Critical patent/JP2010513539A5/ja
Pending legal-status Critical Current

Links

JP2009542980A 2006-12-20 2007-09-14 抗体とその製造法および使用法 Pending JP2010513539A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87106906P 2006-12-20 2006-12-20
PCT/US2007/078568 WO2008079466A1 (en) 2006-12-20 2007-09-14 Antibodies and methods for making and using them

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013169145A Division JP2014028812A (ja) 2006-12-20 2013-08-16 抗体とその製造法および使用法

Publications (2)

Publication Number Publication Date
JP2010513539A JP2010513539A (ja) 2010-04-30
JP2010513539A5 true JP2010513539A5 (OSRAM) 2010-09-30

Family

ID=39536929

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009542980A Pending JP2010513539A (ja) 2006-12-20 2007-09-14 抗体とその製造法および使用法
JP2013169145A Pending JP2014028812A (ja) 2006-12-20 2013-08-16 抗体とその製造法および使用法
JP2015056137A Pending JP2015145394A (ja) 2006-12-20 2015-03-19 抗体とその製造法および使用法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013169145A Pending JP2014028812A (ja) 2006-12-20 2013-08-16 抗体とその製造法および使用法
JP2015056137A Pending JP2015145394A (ja) 2006-12-20 2015-03-19 抗体とその製造法および使用法

Country Status (10)

Country Link
US (3) US8465741B2 (OSRAM)
EP (3) EP2716658A3 (OSRAM)
JP (3) JP2010513539A (OSRAM)
KR (2) KR101546441B1 (OSRAM)
CN (2) CN101675074B (OSRAM)
AU (1) AU2007338607B2 (OSRAM)
BR (1) BRPI0720565A2 (OSRAM)
CA (2) CA2832111A1 (OSRAM)
MX (1) MX2009006659A (OSRAM)
WO (2) WO2008079466A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0720565A2 (pt) * 2006-12-20 2013-09-17 Mmr Information Systems Inc anticorpos e mÉtodos para a sua preparaÇço e seu uso
CA2744103C (en) 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
KR20230044026A (ko) 2010-02-24 2023-03-31 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
RU2012153241A (ru) * 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. Антитела к fgfr2
CA2822969C (en) * 2010-12-31 2018-03-13 Jay M. Short Comprehensive monoclonal antibody generation
AU2011352205B2 (en) 2010-12-31 2016-06-16 Bioatla, Llc Express humanization of antibodies
US8741298B2 (en) * 2011-02-07 2014-06-03 Neotope Biosciences Limited APOE immunotherapy
UA125636C2 (uk) 2011-04-01 2022-05-11 Іммуноджен, Інк. Способи ідентифікації раку, який може реагувати на анти-folr1 антитіло або анти-folr1 імунокон'югат
RU2623122C2 (ru) 2011-10-26 2017-06-22 Новартис Тиргезундхайт АГ Моноклональные антитела и способы их применения
US12384848B2 (en) 2011-12-19 2025-08-12 The Rockefeller University Anti-inflammatory polypeptides
EP2793943B1 (en) 2011-12-19 2018-09-26 The Rockefeller University Non-sialylated anti-inflammatory polypeptides
JP6293147B2 (ja) 2012-08-31 2018-03-14 イミュノジェン, インコーポレイテッド 葉酸受容体1の検出のための診断分析およびキット
US10117933B2 (en) 2012-11-28 2018-11-06 Emergent Biosolutions Canada Inc. Antibodies against Clostridium difficile
LT3038650T (lt) 2013-08-30 2021-09-10 Immunogen, Inc. Antikūnai ir foliatų receptoriaus 1 nustatymo testai
KR20230028600A (ko) 2015-03-04 2023-02-28 더 락커펠러 유니버시티 항염증성 폴리펩타이드
EP3349796A4 (en) 2015-09-17 2019-05-29 ImmunoGen, Inc. THERAPEUTIC COMBINATIONS WITH ANTI-FOLR1 IMMUNOCONJUGATES
AU2017292752B2 (en) 2016-07-06 2023-07-27 Celgene Corporation Antibodies with low immunogenicity and uses thereof
CA3057447A1 (en) 2017-08-03 2019-02-07 Alector Llc Anti-cd33 antibodies and methods of use thereof
CA3109726A1 (en) * 2018-08-31 2020-03-05 Immune Biosolutions Inc Antibodies specific for ntsr1 and uses thereof
CN111662382A (zh) * 2019-03-06 2020-09-15 瑞阳(苏州)生物科技有限公司 特异结合cd3的抗体、抗原结合片段和单链抗体可变区片段及其应用
JP7370569B2 (ja) * 2019-08-07 2023-10-30 国立大学法人 大分大学 アミロイドβタンパク質オリゴマーと結合するヒト化抗体
WO2021216972A1 (en) * 2020-04-24 2021-10-28 Memorial Sloan Kettering Cancer Center Anti-cd3 antibodies and uses thereof
EP4256566A4 (en) * 2020-12-07 2025-02-26 ABSCI Corporation SYSTEMS AND METHODS FOR THE PRODUCTION OF DISEASE-ASSOCIATED PROTEIN COMPOSITIONS
WO2025024323A1 (en) * 2023-07-21 2025-01-30 Bighat Biosciences, Inc. P- and e-selectin-binding compositions and methods of use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0940468A1 (en) * 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
ES2145004T3 (es) * 1991-08-21 2000-07-01 Novartis Ag Derivados de anticuerpos.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
JP2000169393A (ja) * 1998-09-30 2000-06-20 Sankyo Co Ltd 抗Fas抗体を含有する医薬
DE60104282T2 (de) 2000-05-26 2005-10-13 Bristol-Myers Squibb Co. Lösliche mutante ctla4 moleküle und deren verwendung
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
EP2295468B1 (en) * 2002-02-14 2015-07-08 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
US8784821B1 (en) 2003-05-31 2014-07-22 Amgen Research (Munich) Gmbh Human-anti-human cd3 binding molecules
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
KR20120125634A (ko) * 2003-10-16 2012-11-16 마이크로메트 에이지 다중특이적 탈면역화된 cd3-바인더
BRPI0416262B1 (pt) 2003-11-05 2022-04-12 Roche Glycart Ag Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica
WO2005113003A2 (en) * 2004-04-16 2005-12-01 Genentech, Inc. Method for augmenting b cell depletion
WO2005117972A2 (en) 2004-05-05 2005-12-15 Genentech, Inc. Preventing autoimmune disease by using an anti-cd20 antibody
CN101001873B (zh) * 2004-08-04 2013-03-13 曼璀克生物科技有限责任公司 Fc区变体
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2602035C (en) * 2005-03-18 2015-06-16 Medimmune, Inc. Framework-shuffling of antibodies
BRPI0611220A2 (pt) * 2005-06-02 2010-08-24 Astrazeneca Ab anticorpos direcionados para cd20 e usos dos mesmos
MY149159A (en) * 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
BRPI0720565A2 (pt) 2006-12-20 2013-09-17 Mmr Information Systems Inc anticorpos e mÉtodos para a sua preparaÇço e seu uso

Similar Documents

Publication Publication Date Title
JP2010513539A5 (OSRAM)
JP2021191763A5 (OSRAM)
JP2020180158A5 (OSRAM)
JP2009225799A5 (OSRAM)
JP2008542278A5 (OSRAM)
JP2022037133A (ja) 改良された血清アルブミン結合剤
JP2020525032A5 (OSRAM)
JP2021503455A5 (OSRAM)
JP2010536384A5 (OSRAM)
JP2010534478A5 (OSRAM)
JP2018526981A5 (OSRAM)
JP2011207882A5 (OSRAM)
JP2019532619A5 (OSRAM)
JP2013517330A5 (OSRAM)
JP2014511179A5 (OSRAM)
JPWO2015095539A5 (OSRAM)
JP2017533694A5 (OSRAM)
JP2017507652A5 (OSRAM)
JP2012504955A5 (OSRAM)
JP2008532949A5 (OSRAM)
JP2013506428A5 (OSRAM)
JP2016516400A5 (OSRAM)
JP2011517447A5 (OSRAM)
JPWO2020011964A5 (OSRAM)
JP2018518940A5 (OSRAM)